Join the DSEIDE Healthcare Network on WhatsApp!

We are excited to invite you to our exclusive WhatsApp channel dedicated to the healthcare industry! Stay updated with the latest news, insights, innovations, and industry trends curated by DSEIDE Healthcare Network.

📢 Why join?
Get real-time updates on healthcare advancements
Access industry news, research, and networking opportunities
Stay connected with professionals and experts

📲 https://whatsapp.com/channel/0029Vao2rewBfxoAWx9W8y0Pto join now! Let's build a stronger healthcare community together! 🚀💡

Nikhila DseideFounder Bharath DseideFounder PreranaM Coordinator Ishika Coordinator Soumya TS Vaidyog Healthcare Hospex India MEDASUS HEALTHCAREPRIVATELIMITED Amol BK Chandan Prasad DrSrikanth Kulkarni Vistarogya India Darshan Angadi Srinivas Bakki Aspirar SpherePvtLtd Akhila Kosuru Manipal BioIncubator Akhil Dave Varun Nair RootstoCusps PrivateLimited Sunil Harry GeriatricSocietyofIndia 2024 MirMahmood Ali KOACH BOX Bio nutriz DocTrue Technologies ForU medic Sandeep P @OQULIX AdvaithGlobal Services Runalika Roy GMEC India2025 Curo Pharma Anoop Dewan Dr. PadmaSree Dr logy [DrMoopensiNEST|BioNEST] TERN Group Aiprus AI Biosysion DX Bio5 IraLabs Akhila Kosuru Akhil Dave Medidocs Healthcare

Healthcare innovations deserve to be heard, recognized, and celebrated !
This time , we’re taking a giant leap forward.

We’re proud to partner with GMEC India 2025 — the biggest international medical expo in Bangalore ! Dseide is always in the first row to build a stronger healthcare community.

🔹 3 Days of Mega Healthcare Innovation
🔹 300+ Stalls | 10,000+ Visitors | 10,000 Sq. Mtr Space
🔹 16 Prestigious Healthcare Awards

A Pavilion Dedicated to the Future of Healthcare !

Out of 300+ stalls, Dseide Healthcare Network and GMEC India directors decided that 80-100 stalls out of 300 will be dedicated to innovative healthcare startups .

Medical Equipment
Healthcare AI & MedTech
HealthTech & Digital Health
Innovative Product & Service-Based Startups

Join the Healthcare Startup Pavilion — Powered by Dseide Healthcare Network !

We’re proud to be the official startup partner, managing all startup bookings & pavilion operations for this mega event.

Calling all healthcare innovators!

If you’re a startup looking for exposure, networking, and funding opportunities, this is where you need to be ! Connect with global leaders, investors, and industry experts.

Know a healthcare startup that should be part of this? Tag them in the comments!

Let’s innovate, collaborate, and shape the future of healthcare together.

Contact us : admin@dseide.com / Dm us !

Nikhila DseideFounder Bharath DseideFounder PreranaM Coordinator Ishika Coordinator Soumya TS Vaidyog Healthcare Hospex India MEDASUS HEALTHCAREPRIVATELIMITED Amol BK Chandan Prasad DrSrikanth Kulkarni Vistarogya India Darshan Angadi Srinivas Bakki Aspirar SpherePvtLtd Akhila Kosuru Manipal BioIncubator Akhil Dave Varun Nair RootstoCusps PrivateLimited Sunil Harry GeriatricSocietyofIndia 2024 MirMahmood Ali KOACH BOX Bio nutriz DocTrue Technologies ForU medic Sandeep P @OQULIX AdvaithGlobal Services Runalika Roy GMEC India2025 Curo Pharma Anoop Dewan Dr. PadmaSree Dr logy [DrMoopensiNEST|BioNEST] TERN Group Aiprus AI Biosysion DX Bio5 IraLabs

Colorectal cancer prevalence in India

• India has the 3rd highest cases of colorectal cancer in the world and 10% of the total cancer cases in India are based on registered cases only.
• Colorectal Cancer is the 4th highest cancer in Men at a CAGR 10.6%.
• Estimated number of new cases 2020-2040 in India will be up by 57.5%.
• India’s mortality rate is the highest in the world due to late-stage detection of the disease.

Current Challenges in India

• There’s a significant lack of awareness about colorectal cancer in India, leading to late-stage diagnoses and poorer outcomes.
• Public health campaigns and educational initiatives are limited compared to other types of cancers.
• Rising incidence rates - among top ten cancers in India due to various factors, including lifestyle changes, dietary habits, and increasing life expectancy.
• Limited access to screening facilities
• High costs associated with screening facilities.
• Cultural and social stigmas.
Current and future colorectal cancer screening strategies
• Throughout the world, the most used approach for colorectal cancer screening is the faecal immunochemical test (FIT).
• Colonoscopy is the most common screening modality in the USA and is also used in many other regions, including, for example, parts of Germany and Poland.
• offering non-invasive tests as a screening option effectively improves adherence to screening.
• There are five blood tests currently being studied as a potential alternative to FIT and colonoscopy for CRC screening.
• Novel imaging tests, such as the colon capsule, mR colonography and the Ct capsule, are also undergoing active investigation.
• Recovery from deferred screening due to the CovID-19 pandemic will require the use of non-invasive screening options to help select patients for colonoscopy.

Innovative Early detection from Biosysion
Colocam DX - FIT Tube – self Test
ColoCam DX FIT Tube® -is most advanced non-invasive Fecal Immunochemical Test is reliable, accurate, and affordable. FIT colon cancer screening test is a proven and recommended colon cancer screening test used by doctors and hospitals worldwide – over-the-counter self-test kit. The ColoCam Tube® self-test is easy to perform in the comfort of your own home and results are ready within five minutes. With ColoCam Tube®, no prescription, doctor's visit, or mailing a sample back to a laboratory is required.

ColoCam DX - FIT DNA
 Colorectal cancer begins when cells in the intestine undergo genetic mutations. Tumour cells shed into the intestines. Stool samples can be examined for tumour DNA using PCR technology.
 Polymerase chain reaction (PCR) is used to rapidly make millions to billions of copies of a specific DNA sample and only requires a very small sample of DNA to amplify it large enough for detailed study.
 ColoCam DX® - FIT DNA utilizes proprietary methods to analyse the cell DNA for specific Tumour markers.
 ColoCam DX® - FIT DNA is designed to detect tumour DNA and detect 95% of colorectal cancer cases – often in the earliest stages of the disease. *
 Ease-of-use drives ongoing patient adherence as the ColoCam DX® - FIT DNA method requires very small samples compared to screening method.